Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: A mixed treatment comparison

European Journal of Health Economics

Volumn 15, Issue SUPPL. 1, 2014, Pages

  Baji, Petra ^a   Péntek, Márta ^a,b   Czirják, László ^c   Szekanecz, Zoltán ^d   Nagy, György ^e   Gulácsi, László ^a   Brodszky, Valentin ^a  

^a Institute of Entrepreneurship and Innovation   (Hungary)

^b Pest Megyei Flor Ferenc Korhaz   (Hungary)

^c UNIVERSITY OF PÉCS   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Arthritis; Biosimilar pharmaceuticals; Meta analysis; Mixed treatment comparison; Rheumatoid

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOSIMILAR AGENT; CERTOLIZUMAB PEGOL; CT P 13; ETANERCEPT; GENERIC DRUG; GOLIMUMAB; INFLIXIMAB; PLACEBO; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; BAYES THEOREM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOTHERAPY; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ARTHRITIS, RHEUMATOID; COMPARATIVE STUDY; MIDDLE AGED; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; BIOSIMILAR PHARMACEUTICALS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84905684573     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0594-4     Document Type: Article

References (66)

1. Yoo, D.H., Hrycaj, P., Miranda, P., Ramiterre, E., Piotrowski, M., Shevchuk, S., Kovalenko, V., Prodanovic, N., Abello-Banfi, M., Gutierrez-Urena, S., Morales-Olazabal, L., Tee, M., Jimenez, R., Zamani, O., Lee, S.J., Kim, H., Park, W., Muller-Ladner, U.: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis(ARD Online First, published on May 21, 2013 as doi:10.1136/annrheumdis-2012-203090. Downloaded from ard.bmj.com on May 23, 2013-Published by group.bmj.com) (2013)
2. Felson, D.T., Anderson, J.J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 36(6), 729-740 (1993)
3. Higgins, J.P.T., Green, S.: Cochrane handbook for systematic reviews of interventions Version 5.0.2 [updated September 2009]. Cochrane Collab (2009)
4. Brodszky, V.: Effectiveness of biological treatments based on ACR70 response in rheumatoid arthritis: indirect comparison and meta-regression using Bayes-model. Orv. Hetil. 152(23), 919-928 (2011)
5. Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., McQuay, H.J.: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1-12 (1996)
6. Olivo, S.A., Macedo, L.G., Gadotti, I.C., Fuentes, J., Stanton, T., Magee, D.J.: Scales to assess the quality of randomized controlled trials: a systematic review. Phys. Ther. 88(2), 156-175 (2008)
7. Ades, A.E., Sculpher, M., Sutton, A., Abrams, K., Cooper, N., Welton, N., Lu, G.: Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 24(1), 1-19 (2006)
8. Lu, G., Ades, A.E.: Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23(20), 3105-3124 (2004)
9. Cohen, S.B., Emery, P., Greenwald, M.W., Dougados, M., Furie, R.A., Genovese, M.C., Keystone, E.C., Loveless, J.E., Burmester, G.R., Cravets, M.W., Hessey, E.W., Shaw, T., Totoritis, M.C.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54(9), 2793-2806 (2006)
10. Emery, P., Keystone, E., Tony, H.P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., Kremer, J.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis. 67(11), 1516-1523 (2008)
11. Genovese, M.C., Becker, J.C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., Li, T., Aranda, R., Hagerty, D.T., Dougados, M.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 353(11), 1114-1123 (2005)
12. Smolen, J.S., Kay, J., Doyle, M.K., Landewe, R., Matteson, E.L., Wollenhaupt, J., Gaylis, N., Murphy, F.T., Neal, J.S., Zhou, Y., Visvanathan, S., Hsia, E.C., Rahman, M.U.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685), 210-221 (2009)
13. Kremer, J.M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I.F., Williams, G.R., Becker, J.C., Hagerty, D.T., Moreland, L.W.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907-1915 (2003)
14. Kremer, J.M., Genant, H.K., Moreland, L.W., Russell, A.S., Emery, P., Abud-Mendoza, C., Szechinski, J., Li, T., Ge, Z., Becker, J.C., Westhovens, R.: Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 144(12), 865-876 (2006)
15. Weinblatt, M., Combe, B., Covucci, A., Aranda, R., Becker, J.C., Keystone, E.: Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum. 54(9), 2807-2816 (2006)
16. Westhovens, R., Robles, M., Ximenes, A.C., Nayiager, S., Wollenhaupt, J., Durez, P., Gomez-Reino, J., Grassi, W., Haraoui, B., Shergy, W., Park, S.H., Genant, H., Peterfy, C., Becker, J.C., Covucci, A., Helfrick, R., Bathon, J.: Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 68(12), 1870-1877 (2009)
17. Takeuchi, T., Matsubara, T., Nitobe, T., Suematsu, E., Ohta, S., Honjo, S., Abe, T., Yamamoto, A., Miyasaka, N.: Phase II dose-response study of abatacept in Japanese patients with active rheumatoid arthritis with an inadequate response to methotrexate. Mod. Rheumatol. 23(2), 226-235 (2013)
18. Furst, D.E., Schiff, M.H., Fleischmann, R.M., Strand, V., Birbara, C.A., Compagnone, D., Fischkoff, S.A., Chartash, E.K.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30(12), 2563-2571 (2003)
19. Keystone, E.C., Kavanaugh, A.F., Sharp, J.T., Tannenbaum, H., Hua, Y., Teoh, L.S., Fischkoff, S.A., Chartash, E.K.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50(5), 1400-1411 (2004)
20. Weinblatt, M.E., Keystone, E.C., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A., Teoh, L.A., Fischkoff, S.A., Chartash, E.K.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48(1), 35-45 (2003)
21. Breedveld, F.C., Weisman, M.H., Kavanaugh, A.F., Cohen, S.B., Pavelka, K., van Vollenhoven, R., Sharp, J., Perez, J.L., Spencer-Green, G.T.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54(1), 26-37 (2006)
22. Kim, H., Lee, S., Song, Y., Yoo, D., Koh, E., Yoo, B., Luo, A.: A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology 10(1), 9-16 (2007)
23. Detert, J., Bastian, H., Listing, J., Weiss, A., Wassenberg, S., Liebhaber, A., Rockwitz, K., Alten, R., Kruger, K., Rau, R., Simon, C., Gremmelsbacher, E., Braun, T., Marsmann, B., Hohne-Zimmer, V., Egerer, K., Buttgereit, F., Burmester, G.R.: Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. Ann. Rheum. Dis. 72(6), 844-850 (2013)
24. Kavanaugh, A., Fleischmann, R.M., Emery, P., Kupper, H., Redden, L., Guerette, B., Santra, S., Smolen, J.S.: Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann. Rheum. Dis. 72(1), 64-71 (2013)
25. Keystone, E., Heijde, D., Mason Jr, D., Landewe, R., Vollenhoven, R.V., Combe, B., Emery, P., Strand, V., Mease, P., Desai, C., Pavelka, K.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58(11), 3319-3329 (2008)
26. Smolen, J., Landewe, R.B., Mease, P., Brzezicki, J., Mason, D., Luijtens, K., van Vollenhoven, R.F., Kavanaugh, A., Schiff, M., Burmester, G.R., Strand, V., Vencovsky, J., van der Heijde, D.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68(6), 797-804 (2009)
27. Choy, E., McKenna, F., Vencovsky, J., Valente, R., Goel, N., Vanlunen, B., Davies, O., Stahl, H.D., Alten, R.: Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology (Oxford) 51(7), 1226-1234 (2012)
28. Weinblatt, M.E., Kremer, J.M., Bankhurst, A.D., Bulpitt, K.J., Fleischmann, R.M., Fox, R.I., Jackson, C.G., Lange, M., Burge, D.J.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340(4), 253-259 (1999)
29. Klareskog, L., van der Heijde, D., de Jager, J.P., Gough, A., Kalden, J., Malaise, M., Martin Mola, E., Pavelka, K., Sany, J., Settas, L., Wajdula, J., Pedersen, R., Fatenejad, S., Sanda, M.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410), 675-681 (2004)
30. Emery, P., Breedveld, F.C., Hall, S., Durez, P., Chang, D.J., Robertson, D., Singh, A., Pedersen, R.D., Koenig, A.S., Freundlich, B.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372(9636), 375-382 (2008)
31. Moreland, L.W., O'Dell, J.R., Paulus, H.E., Curtis, J.R., Bathon, J.M., St Clair, E.W., Bridges Jr, S.L., Zhang, J., McVie, T., Howard, G., van der Heijde, D., Cofield, S.S.: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum. 64(9), 2824-2835 (2012)
32. Keystone, E.C., Genovese, M.C., Klareskog, L., Hsia, E.C., Hall, S.T., Miranda, P.C., Pazdur, J., Bae, S.C., Palmer, W., Zrubek, J., Wiekowski, M., Visvanathan, S., Wu, Z., Rahman, M.U.: Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann. Rheum. Dis. 68(6), 789-796 (2009)
33. Emery, P., Fleischmann, R.M., Moreland, L.W., Hsia, E.C., Strusberg, I., Durez, P., Nash, P., Amante, E.J., Churchill, M., Park, W., Pons-Estel, B.A., Doyle, M.K., Visvanathan, S., Xu, W., Rahman, M.U.: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 60(8), 2272-2283 (2009)
34. Kremer, J., Ritchlin, C., Mendelsohn, A., Baker, D., Kim, L., Xu, Z., Han, J., Taylor, P.: Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum. 62(4), 917-928 (2010)
35. Tanaka, Y., Harigai, M., Takeuchi, T., Yamanaka, H., Ishiguro, N., Yamamoto, K., Miyasaka, N., Koike, T., Kanazawa, M., Oba, T., Yoshinari, T., Baker, D.: Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann. Rheum. Dis. 71(6), 817-824 (2012)
36. Maini, R., St Clair, E.W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., Lipsky, P.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194), 1932-1939 (1999)
37. St Clair, E.W., van der Heijde, D.M., Smolen, J.S., Maini, R.N., Bathon, J.M., Emery, P., Keystone, E., Schiff, M., Kalden, J.R., Wang, B., DeWoody, K., Weiss, R., Baker, D.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50(11), 3432-3443 (2004)
38. Westhovens, R., Yocum, D., Han, J., Berman, A., Strusberg, I., Geusens, P., Rahman, M.U.: The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 54(4), 1075-1086 (2006)
39. Edwards, J.C., Szczepanski, L., Szechinski, J., Filipowicz-Sosnowska, A., Emery, P., Close, D.R., Stevens, R.M., Shaw, T.: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350(25), 2572-2581 (2004)
40. Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A.J., van Vollenhoven, R.F., Li, N.F., Agarwal, S., Hessey, E.W., Shaw, T.M.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54(5), 1390-1400 (2006)
41. Emery, P., Deodhar, A., Rigby, W.F., Isaacs, J.D., Combe, B., Racewicz, A.J., Latinis, K., Abud-Mendoza, C., Szczepanski, L.J., Roschmann, R.A., Chen, A., Armstrong, G.K., Douglass, W., Tyrrell, H.: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann. Rheum. Dis. 69(9), 1629-1635 (2010)
42. Tak, P.P., Rigby, W.F., Rubbert-Roth, A., Peterfy, C.G., van Vollenhoven, R.F., Stohl, W., Hessey, E., Chen, A., Tyrrell, H., Shaw, T.M.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann. Rheum. Dis. 70(1), 39-46 (2011)
43. Smolen, J.S., Beaulieu, A., Rubbert-Roth, A., Ramos-Remus, C., Rovensky, J., Alecock, E., Woodworth, T., Alten, R.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371(9617), 987-997 (2008)
44. Genovese, M.C., McKay, J.D., Nasonov, E.L., Mysler, E.F., da Silva, N.A., Alecock, E., Woodworth, T., Gomez-Reino, J.J.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58(10), 2968-2980 (2008)
45. Yazici, Y., Curtis, J.R., Ince, A., Baraf, H., Malamet, R.L., Teng, L.L., Kavanaugh, A.: Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann. Rheum. Dis. 71(2), 198-205 (2012)
46. Weinblatt, M.E., Schiff, M., Valente, R., van der Heijde, D., Citera, G., Zhao, C., Maldonado, M., Fleischmann, R.: Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum. 65(1), 28-38 (2013)
47. Schiff, M., Keiserman, M., Codding, C., Songcharoen, S., Berman, A., Nayiager, S., Saldate, C., Li, T., Aranda, R., Becker, J.C., Lin, C., Cornet, P.L., Dougados, M.: Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 67(8), 1096-1103 (2008)
48. Nam, J.L., Ramiro, S., Gaujoux-Viala, C., Takase, K., Leon-Garcia, M., Emery, P., Gossec, L., Landewe, R., Smolen, J.S., Buch, M.H.: Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann. Rheum. Dis. 73 (3), 516-528 (2014). doi:10.1136/annrheumdis-2013-204577
49. Aaltonen, K.J., Virkki, L.M., Malmivaara, A., Konttinen, Y.T., Nordstrom, D.C., Blom, M.: Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE 7(1), e30275 (2012)
50. Blumenauer, B., Judd, M., Cranney, A., Burls, A., Coyle, D., Hochberg, M., Tugwell, P., Wells, G.: Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. (4), CD004525 (2003). http://www.ncbi.nlm.nih.gov/pubmed/14584021
51. Blumenauer, B., Judd, M., Wells, G., Burls, A., Cranney, A., Hochberg, M., Tugwell, P.: Infliximab for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. (3), CD003785 (2002). http://www.ncbi.nlm.nih.gov/pubmed/ 12137712
52. Maxwell, L., Singh, J.A.: Abatacept for rheumatoid arthritis. Cochrane Database Syst. Rev. (4), CD007277 (2009). doi:10.1002/14651858.CD007277.pub2
53. Navarro-Sarabia, F., Ariza-Ariza, R., Hernandez-Cruz, B., Villanueva, I.: Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst. Rev. (3), CD005113 (2005). http://www.ncbi.nlm.nih.gov/pubmed/16034967
54. Ruiz Garcia, V., Jobanputra, P., Burls, A., Cabello, J.B., Galvez Munoz, J.G., Saiz Cuenca, E.S., Fry-Smith, A.: Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst. Rev. (2), CD007649 (2011). doi:10.1002/14651858.CD007649.pub2
55. Singh, J.A., Beg, S., Lopez-Olivo, M.A.: Tocilizumab for rheumatoid arthritis. Cochrane Database Syst. Rev. (7), CD008331 (2010). doi:10.1002/14651858.CD008331.pub2
56. Singh, J.A., Noorbaloochi, S., Singh, G.: Golimumab for rheumatoid arthritis. Cochrane Database Syst. Rev. (1), CD008341 (2010). doi:10.1002/14651858.CD008341
57. Alonso-Ruiz, A., Pijoan, J.I., Ansuategui, E., Urkaregi, A., Calabozo, M., Quintana, A.: Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 9, 52 (2008)
58. Singh, J.A., Christensen, R., Wells, G.A., Suarez-Almazor, M.E., Buchbinder, R., Lopez-Olivo, M.A., Ghogomu, E.T., Tugwell, P.: A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 181(11), 787-796 (2009)
59. Devine, E.B., Alfonso-Cristancho, R., Sullivan, S.D.: Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy 31(1), 39-51 (2011)
60. Guyot, P., Taylor, P., Christensen, R., Pericleous, L., Poncet, C., Lebmeier, M., Drost, P., Bergman, G.: Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther 13(6), R204 (2011)
61. Hochberg, M.C., Berry, S., Broglio, K., Rosenblatt, L., Nadkarni, A., Trivedi, D., Hebden, T.: Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis. Curr. Med. Res. Opin. 29(10), 1213-1222 (2013)
62. Launois, R., Avouac, B., Berenbaum, F., Blin, O., Bru, I., Fautrel, B., Joubert, J.M., Sibilia, J., Combe, B.: Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. J. Rheumatol. 38(5), 835-845 (2011)
63. Schmitz, S., Adams, R., Walsh, C.D., Barry, M., FitzGerald, O.: A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann. Rheum. Dis. 71(2), 225-230 (2012)
64. Turkstra, E., Ng, S.K., Scuffham, P.A.: A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr. Med. Res. Opin. 27(10), 1885-1897 (2011)
65. Points to consider on clinical investigation of medicinal products other than NSAIDS for treatment of rheumatoid arthritis. In: (CPMP), C.f.P.M.P. (ed). EMEA, (2003)
66. Gulácsi, L., Érsek, K., Péntek, M., Brodszky, V.: A certolizumab pegol hatásossága és biztonsá gossága rheumatoid arthritisben. [The efficacy and safety of certolizumab pegol in rheumatoid arthritis.] In: Brodszky V. (szerk). A certolizumab pegol kezelés rheumatoid arthritisben, irodalmi áttekintés és egészség-gazdaságtani elemzés. [Certolizumab pegol treatment in rheumatoid arthritis, literature review and health economic evaluation.] Budapest 2011, Budapesti Corvinus Egyetem Egészség-gazdaságtani és Egészsé gügyi Technológiaelemzési Kutatóközpont, 36-61. (ISBN: 978-963-503-448-2)